Vistaril and Pancytopenia - a phase IV clinical study of FDA data

Summary:

Pancytopenia is reported as a side effect among people who take Vistaril (hydroxyzine hydrochloride), especially for people who are female, 60+ old, have been taking the drug for < 1 month also take Plavix, and have Metastatic renal cell carcinoma.

The phase IV clinical study analyzes which people have Pancytopenia when taking Vistaril. It is created by eHealthMe based on reports of 8,641 people who have side effects when taking Vistaril from the FDA, and is updated regularly.

What is Vistaril?

Vistaril has active ingredients of hydroxyzine hydrochloride. It is often used in stress and anxiety. eHealthMe is studying from 9,565 Vistaril users. Check the latest studies of Vistaril.

What is Pancytopenia?

Pancytopenia (medical condition in which there is a reduction in the number of red and white blood cells, as well as platelets) is found to be associated with 1,793 drugs and 2,431 conditions by eHealthMe. Check the latest studies of Pancytopenia.

On Jul, 16, 2026

8,641 people reported to have side effects when taking Vistaril.
Among them, 19 people (0.22%) have Pancytopenia.

Among these 19 people:

How long have people been on Vistaril when they have Pancytopenia? *

What is the gender of people who have Pancytopenia when taking Vistaril? *

female: 63.16 %
male: 36.84 %

What is the age of people who have Pancytopenia when taking Vistaril? *

What are other drugs people take besides Vistaril? *

What are other side effects people have besides Pancytopenia? *

Fatigue (feeling of tiredness): 6 people, 31.58%
Malaise (a feeling of general discomfort or uneasiness): 6 people, 31.58%
Hypoglycaemic Coma (coma due to deficiency of glucose in the bloodstream): 5 people, 26.32%
Pain: 5 people, 26.32%
Appetite - Decreased (decreased appetite occurs when you have a reduced desire to eat): 5 people, 26.32%
Disease Progression: 5 people, 26.32%
Metastatic Renal Cell Carcinoma (spreadable kidney cell tumour): 5 people, 26.32%
Memory Loss: 4 people, 21.05%
Nausea And Vomiting: 4 people, 21.05%
Acute Kidney Failure: 4 people, 21.05%

What are the existing conditions these people have? *

Metastatic Renal Cell Carcinoma (spreadable kidney cell tumour): 5 people, 26.32%
High Blood Pressure: 2 people, 10.53%
Pain: 2 people, 10.53%
Breast Cancer Metastatic: 2 people, 10.53%
Itching: 2 people, 10.53%
High Blood Cholesterol: 2 people, 10.53%
Hypothyroidism (abnormally low activity of the thyroid gland, resulting in retardation of growth and mental development): 2 people, 10.53%
Schizophrenia (a mental disorder characterized by a breakdown of thought processes): 1 person, 5.26%
Back Pain: 1 person, 5.26%
Bipolar Disorder (mood disorder): 1 person, 5.26%

* Approximation only. Some reports may have incomplete information.

Do you take Vistaril and have Pancytopenia?

- Check whether Pancytopenia is associated with a drug or a condition
- Predict drug outcomes for up to one year with AI
- Get an AI agent to monitor your drugs continuously

Related studies:

Effectiveness of, long term effects of, and alternative drugs to Vistaril:

Vistaril (9,565 reports)

Pancytopenia treatments and more:

Pancytopenia (69,290 reports)

Browse all side effects of Vistaril:

a b c d e f g h i j k l m n o p q r s t u v w x y z

Browse all the drugs that are associated with Pancytopenia:

Pancytopenia (1,793 drugs)

Browse all the conditions that are associated with Pancytopenia:

Pancytopenia (2,431 conditions)

Related publications that referenced our studies

Ate? ?, Arikan MF, Kaplan M, Altay M, "Hydroxyzine induced pancytopenia and petechial rashes: a rare complication", Journal Of Contemporary Medicine, 2017 Jan .
Erden M, Gulcan E, Bilen A, Bilen Y, Uyanik A, Keles M, "Pancytopen? a and Seps? s due to Meropenem: A Case Report", Tropical Journal of Pharmaceutical Research, 2013 Jan .
Ate? ?, Arikan MF, Kaplan M, Altay M, "Hydroxyzine induced pancytopenia and petechial rashes: a rare complication", Journal Of Contemporary Medicine, 2017 Jan .
Erden M, Gulcan E, Bilen A, Bilen Y, Uyanik A, Keles M, "Pancytopen? a and Seps? s due to Meropenem: A Case Report", Tropical Journal of Pharmaceutical Research, 2013 Jan .

How the study uses the data?

The study uses data from the FDA. It is based on hydroxyzine hydrochloride (the active ingredients of Vistaril) and Vistaril (the brand name). Other drugs that have the same active ingredients (e.g. generic drugs) are not considered. Dosage of drugs is not considered in the study.

How to use the study?

DO NOT STOP MEDICATIONS without first consulting your doctor. If there are any serious or long term adverse effects discovered in the study, discuss the study with your doctor to ensure that proper medication management will be in place if applicable.

Who is eHealthMe?

With medical big data and proven AI/ML algorithms, eHealthMe provides a platform for everyone to run phase IV clinical trials. We study millions of patients and 5,000 more each day. Results of our real-world drug study have been referenced on 800+ peer-reviewed medical publications, including The Lancet, Mayo Clinic Proceedings, and Nature. Our analysis results are available to researchers, health care professionals, patients (testimonials), and software developers (open API).

WARNING, DISCLAIMER, USE FOR PUBLICATION

WARNING: Please DO NOT STOP MEDICATIONS without first consulting a physician since doing so could be hazardous to your health.

DISCLAIMER: All material available on eHealthMe.com is for informational purposes only, and is not a substitute for medical advice, diagnosis, or treatment provided by a qualified healthcare provider. All information is observation-only. Our phase IV clinical studies alone cannot establish cause-effect relationship. Different individuals may respond to medication in different ways. Every effort has been made to ensure that all information is accurate, up-to-date, and complete, but no guarantee is made to that effect. The use of the eHealthMe site and its content is at your own risk.

If you use this eHealthMe study on publication, please acknowledge it with a citation: study title, URL, accessed date.